Vitreoscilla Hemoglobin

INTRACELLULAR LOCALIZATION AND BINDING TO MEMBRANES*

RamandeepDagger §, Kwang Woo Hwang§, Manoj RajeDagger , Kyung-Jin Kim, Benjamin C. Stark, Kanak L. DikshitDagger ||, and Dale A. Webster||

From the Dagger  Institute of Microbial Technology, Sector 39, Chandigarh 160014, India, and the  Department of Biological, Chemical, and Physical Sciences, Illinois Institute of Technology, Chicago, Illinois 60616

Received for publication, October 26, 2000, and in revised form, April 23, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The obligate aerobic bacterium, Vitreoscilla, synthesizes elevated quantities of a homodimeric hemoglobin (VHb) under hypoxic growth conditions. Expression of VHb in heterologous hosts often enhances growth and product formation. A role in facilitating oxygen transfer to the respiratory membranes is one explanation of its cellular function. Immunogold labeling of VHb in both Vitreoscilla and recombinant Escherichia coli bearing the VHb gene clearly indicated that VHb has a cytoplasmic (not periplasmic) localization and is concentrated near the periphery of the cytosolic face of the cell membrane. OmpA signal-peptide VHb fusions were transported into the periplasm in E. coli, but this did not confer any additional growth advantage. The interaction of VHb with respiratory membranes was also studied. The Kd values for the binding of VHb to Vitreoscilla and E. coli cell membranes were ~5-6 µM, a 4-8-fold higher affinity than those of horse myoglobin and hemoglobin for these same membranes. VHb stimulated the ubiquinol-1 oxidase activity of inverted Vitreoscilla membranes by 68%. The inclusion of Vitreoscilla cytochrome bo in proteoliposomes led to 2.4- and 6-fold increases in VHb binding affinity and binding site number, respectively, relative to control liposomes, suggesting a direct interaction between VHb and cytochrome bo.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In the years following the discovery of hemoglobin in the Gram-negative bacterium Vitreoscilla in 1986 (1), other hemoglobins and flavohemoglobins have been found in a variety of microbes, indicating the widespread occurrence of Hb-like proteins in the microbial world (2-6). However, at present Vitreoscilla hemoglobin (VHb)1 remains the most studied of these bacterial hemoglobins, including its potential use in biotechnological applications. The cellular concentration of VHb in Vitreoscilla increases roughly two orders of magnitude (to about 50 nmol heme/g wet weight) when the oxygen concentration of its growth medium falls to a microaerobic level (7). Enhanced biosynthesis of VHb is mediated at the transcriptional level by an oxygen-sensitive promoter that turns on under hypoxic conditions (below ~10% of air saturation) in both its native and recombinant host, Escherichia coli (8-11). The presence of a relatively large cellular concentration of VHb under oxygen-limiting conditions suggests that its primary function is to trap molecular oxygen and facilitate its transfer to the respiratory apparatus to enable Vitreoscilla to survive under these conditions despite its being a strict aerobe.

It has been demonstrated through genetic engineering that the intracellular expression of VHb in various heterologous hosts often results in the enhancement of cell density, oxidative metabolism, engineered product formation, and bioremediation, especially under oxygen-limiting conditions. Some examples of the in vivo effects of VHb include (i) increased cell density in recombinant E. coli and Pseudomonads (9, 12-14), (ii) increased production of alpha -amylase in E. coli (15) and cephalosporin C in Acremonium chrysogenum (16), and (iii) enhanced degradation of toxic wastes such as benzoic acid degradation by Pseudomonads (17) and 2,4-dinitrotoluene degradation by Burkholderia (18). Studies conducted so far on biosynthesis, functional characteristics, and genetic regulation of VHb suggest two possible working models to account for the mechanism of VHb action. The first one, called the facilitated diffusion hypothesis (19), implies that the presence of VHb enhances the oxygen flux to one or both of the terminal oxidases (cytochromes bo and bd) under hypoxic conditions. This is supported by the fact that the respiratory activity and ATP production increased in an E. coli strain that contained VHb relative to a control strain lacking VHb (20). The oxygen-binding properties of VHb are presumed to contribute to its postulated function; it has a relatively normal association rate constant (kon) for oxygen binding, thus showing a relatively high "avidity" for oxygen, but its rate constant for oxygen dissociation (koff) is unusually large (21). The relatively large static equilibrium dissociation constant, Kd, which differs 10-fold from the one determined kinetically (22), is 6 µM (equivalent to P50 = 3.3 mm). These oxygen-binding characteristics are consistent with its putative role of sequestering oxygen from the environment and feeding it to the respiratory terminal oxidases. A possible alternative mechanism of action of VHb may be that oxy-VHb influences the activity of some key redox-sensitive component of the cell, which could be a sensor, a regulator, or even an allosteric site of a respiratory enzyme. Such an influence could in turn be transduced into an increase in the efficiency of energy conservation. There is also the possibility that VHb has a totally different function or more than one function. For example, it has recently been demonstrated that the related flavohemoglobin from E. coli is a nitric-oxide dioxygenase that dioxygenates nitric oxide to form nitrate (23) to protect the cell from this free radical that can be generated by oxidation-reduction systems including the respiratory chain.

The proposed function of VHb as an oxygen carrier suggests that close proximity to the respiratory membrane would enable it to perform its cellular function most efficiently. It was reported previously that ~40% of the VHb expressed in E. coli is found in the periplasmic space (24). This result was based on the isolation of periplasmic VHb protein from the recombinant E. coli by lysozyme osmotic shock treatment. Further, a phoA-VHb fusion study indicated that the N terminus of VHb may have a transport function. These observations supported the function of VHb as a facilitator of oxygen transfer by placing it closest to the environmental source of oxygen. However, the N-terminal sequence of VHb is not a typical export signal sequence, and it is known that recombinant protein that is overexpressed in E. coli often ends up in the periplasm or inclusion bodies or is even secreted from the cell (25). On the other hand, the localization of oxy-VHb near the respiratory apparatus would be preferable if VHb facilitates oxygen delivery by generating sufficient oxygen flux and directly interacting with the respiratory apparatus of the cell. In the homologous mitochondrial protein, cytochrome-c oxidase, the oxygen-reactive sites are oriented in the membrane on the cytoplasmic side (26). Thus, a specific cellular location for VHb may be required for the optimal performance of its cellular function. Because the periplasmic localization of VHb was determined through indirect experimental observations and could be an artifact, we reexamined the question of the cellular localization of VHb by determining the location of VHb inside the cell through electron microscopy. This led to a derivative study of the membrane binding properties of VHb. This paper shows that the location of VHb in Vitreoscilla and recombinant E. coli is cytoplasmic and concentrated adjacent to the cell membrane, and evidence is provided that because of its membrane association properties, it may perform its cellular function by interacting directly with the respiratory apparatus of the cell.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Bacterial Strains, Plasmids, and Growth Conditions-- Vitreoscilla sp. strain C1, E. coli JM109, and E. coli BL21DE3 carrying various recombinant plasmid constructs were used for the experimental work. Recombinant plasmid pUC8:16 carrying vgb has been described previously (27). Vitreoscilla was routinely grown in PYA medium (1% peptone, 1% yeast extract, and 0.02% sodium acetate, pH 7.8) at 25 °C. E. coli strains were grown in Luria Broth (1% tryptone, 0.5% yeast extract, and 1% NaCl, pH 7.5) at 37 °C, and the oxygen level was adjusted according to the method adopted by Narro et al. (28) and as described previously (29). The plasmid, Bluescript KS(+), was obtained from Stratagene and the expression-secretion vector, pTMNO (30), was used for the generation of the ompA-vgb gene fusion. E. coli BL21DE3 carrying the ompA-vgb fusion was induced with 0.1 mM isopropyl-1-thio-beta -D-galactopyranoside to induce VHb. Ampicillin was added when needed at 50 µg/ml.

Generation of Antibodies-- The antibodies against VHb were generated as described (29) and saturated against a crude extract of E. coli. The specificity of the antibodies was determined by Western blotting using standard protocol.

Immunogold Electron Microscopy of E. coli Containing VHb-- Cells were harvested in late log phase for both the high aeration studies (grown at 200 rpm in 500-ml baffled flasks containing 100 ml of medium) and the low aeration studies (grown at 75 rpm in 500-ml flasks containing 300 ml of medium) by centrifugation (5,000 × g at 4 °C), washed twice with Dulbecco's phosphate-buffered saline (PBS), and resuspended in 0.2% glutaraldehyde plus 4% paraformaldehyde for 20 min. Cells were then dehydrated with a graded series of ethanol and embedded in LR White resin (polymerization at 55 °C for 24 h). Ultrathin sections cut with a Reichert Ultracut Ultramicrotome (Leica Reichart Jung, Austria) were picked up on 200-mesh nickel grids. Nonspecific binding sites were blocked with 2% skim milk/0.001% Tween 20 in PBS (blocking buffer). The grids carrying the ultrathin sections were then washed in 0.05% Tween 20 in PBS (washing buffer) and incubated overnight with rabbit anti-VHb antibody (diluted 1:500 in 1:10 diluted blocking buffer) at 4 °C. The grids were then washed in the washing buffer and incubated for 2 h at room temperature with goat anti-rabbit antibody conjugated to 10-nm colloidal gold spheres (diluted 1:20 in 1:10 diluted blocking buffer). This was followed by washing the grids in washing buffer and subsequently in distilled water. The sections were then stained in 2% aqueous uranyl acetate for 40 min in the dark followed by a final washing with double-distilled water. The grids thus prepared were examined in a JEOL 1200 EXII transmission electron microscope (TEM, operating voltage 60-80 kV), and random fields were photographed. The prints of the micrographs were then made at the desired magnification for further analysis. Controls included the labeling of each set of samples with the preimmune serum (i.e. normal rabbit serum) instead of anti-VHb serum. E. coli cells not expressing VHb were also included as a control for the recombinant E. coli.

Estimation of the Distribution of VHb in the Cytosol of E. coli-- Prints of the negatives were made and overlaid with transparency sheets. Cell outlines clearly delineating the outer and inner membranes were traced, cut out, and weighed. The gold particles in the cytoplasm and periplasm of each section were counted with the help of an ×5 magnifying glass. The area of each section was computed by comparison with the weight of an area corresponding to 100 square microns cut out from the same transparency sheet. To calculate the probe density in the two cellular compartments, at least 35 sections were analyzed per sample, and the results were subjected to statistical analysis using Sigma Plot (version 3.0) and t tests to test the level of significance. A more detailed description of the immunogold labeling procedure and analytical methods are described by Ramandeep et al. (31).

Construction of ompA-vgb Gene Fusion-- An NcoI site was incorporated at the N terminus of vgb by PCR using the oligomer HB-P (below). The C-terminal oligomer HB-3 used for amplification incorporated a BamHI site. The sequences of these primers are HB-P (5'-GCCATGGCAGACCAGCAAACCATTAAC-3') and HB-3 (5'-GGGATCCGTTTTGGCCAACAGCCAAACTGCTGCTGTG-3'). The restriction sites are underlined.

The amplified product was cloned in pBluescript KS(+), and its complete nucleotide sequence was checked to validate the authenticity of the clone. The NcoI-BamHI fragment was then ligated in frame with the OmpA signal peptide-coding sequences carried on the expression-secretion vector pTMN (30). The fusion junction of ompA and vgb was ascertained through nucleotide sequencing.

Preparation of Membranes and Proteoliposomes-- Membranes of both E. coli and Vitreoscilla were obtained by lysozyme treatment of the cells as described previously (32). These were sonicated for 5 min at 25% duty cycle at full power with a Branson Sonifier Cell Disruptor 35 fitted with a microtip to produce the inverted membrane vesicles. Phospholipids purified from Vitreoscilla (33) were used to make liposomes that were produced by suspending 62 mg of the phospholipids in 2.0 ml of 25 mM Tris-Cl, pH 7.2, and sonicating for 1 min at 0 °C. Cytochrome bo proteoliposomes were prepared using a modification of a procedure described previously (33) by adding purified cytochrome bo to the liposomes at a protein/lipid ratio of 1:150, adding octyl glucoside at a final concentration of 1.25% and slowly stirring at 0 °C for 30 min. The suspension was diluted with 20 volumes of the Tris buffer and incubated at room temperature for 20 min. The proteoliposomes were then collected by centrifugation at 120,000 × g for 2 h at 4 °C and stored at -70 °C.

Purification of VHb and Cytochrome bo-- The VHb was purified by a modification of the procedure described previously (34): lysozyme lysis of Vitreoscilla cells, 45-70% ammonium sulfate fractionation, DEAE-cellulose chromatography, and Sephadex G-100 chromatography. Cytochrome bo from Vitreoscilla was also purified by the modification of a published method (35). The membranes obtained by lysozyme treatment were extracted with deoxycholate followed by chromatography first on Bio-Gel A (0.5 M) and then on DEAE-Sepharose CL-6B.

Assay for Ubiquinol-1 Oxidase Activity-- The assay medium contained 60 mM Tris-Cl, pH 7.7, 400-500 µg of membrane protein or 0.16 µg of cytochrome bo in the proteoliposomes, and 10 mM dithiothreitol in a final volume of 3.65 ml. After a 2-min preincubation at 30 °C, 15 µM ubiquinol-1 was added to start the reaction, which was monitored polarographically for 4 min at 30 °C using a YSI Model 53 oxygen monitor. The O2 uptake in the absence of membranes was measured similarly to correct for the autoxidation of ubiquinol-1. This assay was performed at normal conditions (100% atmospheric O2 saturation) and hypoxic conditions (18-22% of atmospheric O2 saturation). Hypoxic conditions were produced by bubbling the reaction mixture (minus the ubiquinol-1) in a special test tube containing a long needle connected to a nitrogen gas supply, a tube connected to a vacuum pump, and sealed with cork and parafilm. Nitrogen gas was bubbled for 5 min, and then the gas phase inside the test tube was evacuated for 5 min. These steps were repeated four times, and then the reaction buffer was transferred using another long needle back to the oxygen monitor to determine the oxygen concentration and start the reaction with ubiquinol-1.

Determination of Binding of Hbs to Membranes-- This is an adaptation of a procedure that was originally developed for studying the binding of ligands to proteins (36). The Sephadex G-50 used in the original method was replaced by Sephadex G-100, which with its larger pore size excludes membrane fragments but not Hb from the gel. After mixing the Sephadex, the Hb, and membrane fragments and allowing the suspension to settle, the Hb concentration in the supernatant was determined. If the Hb has a binding affinity for the membrane, the Hb concentration in the external gel space will be higher in the presence of the membranes than in their absence. The following equations summarize the procedure used.


<UP>Hb</UP>=<UP>Hb<SUB>o</SUB></UP>+<UP>Hb<SUB>i</SUB></UP> (Eq. 1)

<UP>Hb<SUB>i</SUB></UP>=<UP>Hb</UP>−<UP>Hb<SUB>o</SUB></UP>=<UP>Hb</UP>(<UP>1</UP>−&bgr;/&agr;) (Eq. 2)
Hb is the amount of hemoglobin added, Hbo and Hbi are the amounts outside and inside the gel, respectively, alpha  is the ratio of the concentration of membranes (in terms of protein content) outside the gel to that of the membrane solution added to the dried gel, and beta  is defined as the ratio of the hemoglobin concentration outside the gel to that of the solution of hemoglobin added. alpha  is determined by plotting the amount of membrane fragments outside the gel versus the amount of membrane fragments added, as illustrated in Fig. 1 for Vitreoscilla membranes, and beta  is determined as shown in Fig. 2 for control horse hemoglobin. Because
<UP>Hb<SUB>o</SUB></UP>=<UP>Hb<SUB>o</SUB></UP>{<UP>free</UP>}+<UP>Hb<SUB>o</SUB></UP>{<UP>bound</UP>} (Eq. 3)
it can be shown that the concentrations of the bound and free hemoglobin outside the gel are
<UP>Hb<SUB>o</SUB></UP>{<UP>bound</UP>}=<UP>Hb<SUB>o</SUB></UP>−<UP>Hb<SUB>o</SUB></UP>{<UP>free</UP>}=<UP>Hb</UP>(<UP>&bgr;</UP>−&bgr;′)/(&agr;−&bgr;′), <UP>and</UP> (Eq. 4)

<UP>Hb<SUB>o</SUB></UP>{<UP>free</UP>}=&bgr;′(&agr;−&bgr;)/(&agr;−&bgr;′) (Eq. 5)
where beta ' is defined as beta  in the absence of the membranes.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Determination of alpha  for Vitreoscilla membranes. See "Materials and Methods" for experimental details.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Determination of beta  for control horse Hb. See "Materials and Methods" for experimental details. a, no membranes added; b, 0.7 mg of protein/ml of Vitreoscilla membranes added; c, 1.4 mg of protein/ml of Vitreoscilla membranes added.

The final operational equation is a modified Scatchard equation,
1/R=K<SUB><UP>d</UP></SUB>/N(<UP>Hb<SUB>o</SUB></UP>{<UP>free</UP>})+1/N, (Eq. 6)
where R = Hbo{bound}/mg membrane, Kd = dissociation constant for the hemoglobin binding to the membranes, Hbo{free} = concentration of unbound hemoglobin, and N = the maximum number of binding sites per mg membrane.

Experimentally, 50 mg of the dried Sephadex G-100 was suspended in 1.5 ml of 0.1 M potassium phosphate, pH 7.2, and allowed to swell for 4 h at room temperature, and then 0.5 ml of the buffer solution containing the membranes and/or globins was added. This suspension was incubated for 10 min at room temperature with continuous stirring, the resin was allowed to settle for 10 min, and a 100-µl aliquot of the supernatant was removed. The globin concentration was determined by using heme absorption at A410 (179, 188, and 214 mM-1 cm-1 for equine Hb, Mb, and VHb, respectively), membrane protein using A280 (E = 0.675 ml mg-1 cm-1, corrected for globin protein when present), and liposome concentration by measuring the inorganic phosphate released after total hydrolysis using the Fiske-Subbarow colorimetric method (37).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Immunolocalization of VHb in Vitreoscilla-- A previous study of VHb indicated that this bacterial hemoglobin is partially transported into the periplasmic space both in its native host, Vitreoscilla, and recombinant host, E. coli (24). The question of the subcellular location of VHb was addressed further by tracing it in Vitreoscilla using immunogold electron microscopy. Vitreoscilla cells grown under high and low aeration were probed with an anti-VHb antibody and examined with an electron microscope. Vitreoscilla cells cultivated at low aeration had a significantly higher level of labeled VHb (as compared with aerobically grown cells), which was predominantly cytoplasmic (Fig. 3). The standardized results indicated that more than 90% of the VHb was confined to the cytoplasm (Table I), much of it adjacent to the cytoplasmic membranes; of the total signal in the cytoplasm, 57% of the VHb-bound gold particles were found localized within 0.1 µm of the inner membrane (Table II).


View larger version (105K):
[in this window]
[in a new window]
 
Fig. 3.   Immunolocalization of VHb in Vitreoscilla cells grown under low aeration probed with anti-VHb antibody (a) or preimmune serum (b). Arrow heads, gold particles; cy, cytoplasm; p, periplasm; bar, 0.5 µm.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Distribution of VHb in Vitreoscilla cells as determined by immunogold electron microscopy

                              
View this table:
[in this window]
[in a new window]
 
Table II
Distribution of VHb within the cytoplasm as determined by immunogold electron microscopy

Immunolocalization of VHb in Recombinant E. coli-- VHb expressed in E. coli through multicopy plasmids usually amounts to 5-10% of the total cellular protein. Because an osmotic shock method used to release periplasmic protein in recombinant E. coli indicated the partial transport of VHb into the periplasm, we reexamined the location of VHb in recombinant E. coli using immunogold electron microscopy. Cells grown under high and low aeration were probed with gold-labeled anti-VHb. The expression of VHb in E. coli led to an almost exclusive cytoplasmic labeling without any significant signal for the presence of VHb in the periplasm (Fig. 4 and Table III). These results coincided with the observations made on Vitreoscilla as did the localization of the VHb adjacent to the cytoplasmic membrane: 54% within 0.1 µm of the inner membrane (Table II). Because VHb is so highly expressed in E. coli, the immunogold signals were much stronger than in Vitreoscilla (Figs. 4 and 3, respectively). Although the primary goal of the immunogold labeling procedure was localization and not quantitation, the efficiency of the labeling can be roughly estimated from the section thickness, 70 nm as indicated by the interference color of the sections, and the gold particle density, 27/µm2. Assuming a concentration of 25 nmol of dimeric VHb/g wet weight of cells, the efficiency was only ~3%. This probably underestimates the efficiency, however, because a large fraction of the slices (~40%) inexplicably had few or no particles, whereas some had over 10 times the number of particles per µm2.


View larger version (124K):
[in this window]
[in a new window]
 
Fig. 4.   Immunolocalization of VHb in E. coli carrying vgb. a, under high aeration probed with anti-VHb antibody; b, under low aeration probed with an anti-VHb antibody; c, cells probed with preimmune serum. Gold particles are indicated by arrow heads, especially in the section marked with a. cy, cytoplasm; p, periplasm; bar, 0.5 µm.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Distribution of VHb in recombinant E. coli cells as determined by immunogold electron microscopy

OmpA-VHb Fusion and Periplasmic Transport-- To establish that VHb can be transported via a full-fledged transport signal and to monitor the effect of accumulation of periplasmic VHb on the physiology of its host, an OmpA-VHb fusion was created, and localization of VHb was monitored through immunogold electron microscopy. In contrast to native VHb, a high level of periplasmic VHb accumulated via OmpA-VHb fusion in E. coli (Fig. 5). Growth characteristics and oxygen uptake of E. coli carrying the OmpA-VHb fusion were found to be similar to E. coli carrying native VHb, indicating that accumulation of VHb in the periplasm does not confer an advantage over cytoplasmic VHb.


View larger version (140K):
[in this window]
[in a new window]
 
Fig. 5.   Immunolocalization of the ompA-vgb fusion in E. coli. a, probed with anti-VHb antibody 1.5 h after induction; b, probed with anti-VHb antibody 3 h after induction; c, probed with preimmune serum. Arrow heads, gold particles; cy, cytoplasm; p, periplasm; bar, 0.5 µm.

Binding of VHb and Control Equine Hb and Mb to Bacterial Membranes-- A plot of 1/R versus 1/Hb{free} is illustrated in Fig. 6 for VHb binding to Vitreoscilla membranes. The Kd is obtained from the slope, and N (the maximum number of VHb molecules bound/mg of membrane protein) is obtained from the intercept. Table IV summarizes the data for the binding of three different Hbs to three different membrane preparations. From these data, VHb has ~4-8 times higher affinity for Vitreoscilla membranes than the control equine Hbs have for these membranes. Surprisingly, VHb also has about the same high affinity for E. coli membranes. To test whether there are binding sites accessible only on the cytosolic side of the plasma membrane, membrane vesicles were prepared from the membranes by sonication, which effectively reverses their topology. However, there was essentially no difference in binding of the VHb to these inside-out membranes compared with the periplasmic side-out membranes (Table IV). Neither of the horse globins showed any significant difference in binding to these two Vitreoscilla membrane preparations.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   Plot of 1/R versus 1/VHb{free} for VHb binding to Vitreoscilla membranes. The y intercept is 1/N, and the slope is Kd/N.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Kd values for binding of VHb, horse Mb, and horse Hb to Vitreoscilla and E. coli membranes

Although the horse globins have a lower binding affinity than VHb to all three membrane preparations, there seem to be more binding sites for them with N being around 32 nmol/mg of membrane protein for each of them versus only 7 nmol/mg of membrane protein for VHb. This indicates that horse Mb and Hb bind to a number of nonspecific sites with relatively low affinity, whereas VHb interacts with a limited number of higher affinity sites. Likely sites of interaction would be components of the respiratory chain. This possibility was examined using proteoliposomes containing purified Vitreoscilla cytochrome bo, which had been purified previously in our laboratory.

Binding of VHb and Control Equine Hb and Mb to Cytochrome bo Proteoliposomes-- For this experiment, horse Mb and Hb were again used as control Hbs, and liposomes without cytochrome bo incorporated were used as control for the proteoliposomes. The results (Table V) indicate that this terminal oxidase may be one of the sites in the membrane for VHb binding. Compared with the control equine globins, VHb had 5-11 times the binding affinity for the cytochrome bo proteoliposomes. VHb also had 2.4 times the affinity for the proteoliposomes than for the control liposomes; but more significantly, N, the number of binding sites, averaged 0.21 nmol/mM phospholipid phosphate for the proteoliposomes and 0.034 nmol/mM phospholipid phosphate for the control liposomes.

                              
View this table:
[in this window]
[in a new window]
 
Table V
Kd for binding of VHb, horse Mb, and horse Hb to cytochrome bo proteoliposomes and control liposomes

Effect of VHb on the Respiratory Activity of Membranes-- Because the above results indicated that VHb interacts with bacterial membranes, a logical next step was to test the effect of VHb on the respiration of these membranes. For this, we used their ubiquinol-1 oxidase activity and looked at the effect of VHb at both normal and hypoxic conditions (Figs. 7 and 8, respectively). VHb stimulated this respiratory activity in all cases tested, the largest effect being for inside-out Vitreoscilla membranes, especially under hypoxic conditions.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of VHb on the ubiquinol-1 oxidase activity of Vitreoscilla membranes, Vitreoscilla membrane vesicles (sonicated membranes), and E. coli membranes under saturating aerobic conditions (236 µM O2). VHb (0.7 µM) increased the oxygen uptake of Vitreoscilla membranes by 11%, Vitreoscilla membrane vesicles (sonicated membranes) by 42%, and E. coli membranes by 12%. Values are averages of three individual measurements. Error bars, standard error of the mean.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of VHb on the ubiquinol-1 oxidase activity of Vitreoscilla membranes, Vitreoscilla membrane vesicles (sonicated membranes), and E. coli membranes under hypoxic conditions (47 µM O2). VHb (0.7 µM) increased oxygen uptake by 26% in Vitreoscilla membranes, by 68% in Vitreoscilla membrane vesicles, and by 59% in E. coli membranes. Values are averages of three individual measurements. Error bars, standard error of the mean.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A model for studying oxygen transfer to living cells is the Vitreoscilla-VHb system, the VHb being synthesized when environmental oxygen becomes limiting. How the presence of VHb enables the bacterium to grow better under oxygen limitation is not conclusively known, but knowledge of its subcellular localization is vital to understanding its function. The ultrastructural studies described here have established the cytoplasmic location of hemoglobin, both in Vitreoscilla and recombinant E. coli overexpressing VHb. Although cells grown under low oxygen synthesize large amounts of VHb in E. coli, little VHb-specific signal was detected in the periplasm, a result in contrast to a previous study, which indicated that ~40% of the VHb in E. coli was located in the periplasmic space (24). It might seem that a periplasmic location would have the advantage of locating the VHb closest to the source of environmental oxygen. However, the accumulation of large amounts of oxy-Hb in the relatively small volume of the periplasm may change the redox environment of the periplasm, which may not be favorable to the cell. On the other hand, the presence of VHb in the cytosol may provide an oxygen buffer, and its subcellular localization in close proximity to the cell membrane could facilitate oxygen transfer to the oxygen-binding sites of the terminal oxidases that are oriented toward the cytoplasm (26, 38). Thus, a cytoplasmic localization of VHb in the proximity of respiratory membranes, as demonstrated in the present study, is consistent with its proposed function to feed molecular oxygen to the respiring membranes under oxygen limitation.

Although the detection of VHb in the periplasmic fraction in the 1989 study (24) could have been an experimental artifact of VHb leakage through the membranes during osmotic shock, it is more likely the result of overproduction and extrusion of the VHb, because the extrusion of overproduced cytoplasmic recombinant proteins into the periplasmic space has often been observed (25). Generally, true periplasmic proteins are compartmentalized in the periplasmic space and not divided between there and the cytoplasm. In the work reported here, virtually no VHb was detected in the periplasmic space, but VHb leakage from recombinant E. coli has occasionally been observed while washing harvested cells with buffer.2 The extrusion of VHb could be a function of growth medium, growth phase, physiological state of the cells, the strain of E. coli bearing the vgb, other genetic determinants, etc.

Based on the finding of VHb in the periplasmic space, it was proposed (24) that the first 16 N-terminal residues of VHb may be an export signal, but this N-terminal sequence does not conform to the usual signal-peptide characteristics, and it was not excised during transport; further, unlike most transport signals, it is important for the protein function. The first 16 residues of VHb are an integral part of the A-helix structure (39), and a VHb mutant lacking the first 14 N-terminal residues is incapable of binding heme.3 In the present study, VHb was determined to have a cytosolic location, raising the question of whether VHb can be transported into the periplasmic space and whether a periplasmic location is in any way superior to a cytoplasmic localization. The OmpA-VHb fusion study clearly suggested that there is no hindrance to the transport of VHb across the membrane by the structure or folding of the protein per se, because ~50% of the peptide-VHb fusion protein was localized in the periplasm. This enhanced periplasmic localization did not provide any distinct advantage over the cytoplasmic accumulation of VHb under oxygen-limited growth conditions. However, the lack of an effect could be caused by the accumulation of nonfunctional apoprotein in the periplasmic space, which has been observed for E. coli flavohemoglobin (40).

If the primary function of VHb is to trap and feed oxygen to the membrane-bound terminal oxidases, it may actually associate with the cellular membrane to facilitate this process. Initial evidence for this association was the observation that the respiratory membranes of lysed Vitreoscilla cells retained significant amounts of VHb, and extensive washing of the membrane fragments was required to remove it (35). The study of VHb binding to bacterial membranes in the present work found Kd values that were in the micromolar range, 5.4-6.5 µM (Table IV), which were 4.2-8.3 and 4.1-8.6 times greater than the affinities of the control equine globins for Vitreoscilla and E. coli membranes, respectively. Assuming a value of 50 nmol of VHb heme/g wet weight of bacterial cells (7-9), it can be estimated that there will be about 15,000 molecules of dimeric VHb per bacterial cell. From the N value of 7 nmol of binding sites/mg of membrane protein, it can be estimated that there are roughly four times as many VHb binding sites (69,000) in the membrane of a single bacterial cell as there are VHb molecules in the cell. For a Kd of 6 µM, this would indicate that most of the VHb would be bound (94%). For comparison, the Kd for human Hb binding to human red blood cell membranes is 1.0 × 10-4 M, which was considered physiologically significant (41). Thus, the affinity of VHb for bacterial membranes is likely to be important physiologically and is very probably the reason for the subcellular localization of VHb adjacent to the cellular membrane.

The binding of VHb could involve interactions of residues with membrane lipids and/or specific membrane proteins. In the globin domains of flavohemoglobins, which are structurally similar to VHb, Lys-11 is generally conserved (39). Thus, a hydrophobic N terminus carrying a positively charged residue (Lys-11 in VHb) could play a role in the interaction of VHb with the membrane. Lys-11 is an obvious target for site-directed mutagenesis to test whether it plays any role in the membrane interactions of VHb. Whatever the mechanism by which VHb associates with membranes, binding studies with proteoliposomes implicated an interaction with a specific protein, the cytochrome-bo terminal oxidase. When this protein was incorporated into liposomes, the affinity for VHb increased 2.4 times relative to the control liposomes without the cytochrome, and the number of binding sites for VHb increased 6.1-fold to 0.21 nmol/µmol of liposomal phospholipid phosphate. Using this latter value and assuming a molecular mass of 700 daltons for a phospholipid molecule, there are 4,760 molecules of phospholipid for each binding site. Because the proteoliposomes were made using a cytochrome bo/phospholipid ratio of 1:150 (weight/weight), there will be ~1 cytochrome bo incorporated for every 2,240 phospholipid molecules, about twice as many protein molecules as binding sites. Although these estimates may be fortuitous, previous work has indicated that the cytochrome bo in these proteoliposomes is randomly oriented, i.e. 50% in the inside-out and 50% in the outside-in orientation (33). Thus, there may be preferential binding to one side of the cytochrome. Although the binding experiment with inverted membrane vesicles (Table IV) was inconclusive, VHb did stimulate the ubiquinol-1 respiratory activity of inverted membrane vesicles significantly more than that of periplasmic side-out membranes (Figs. 7 and 8), suggesting a preference for cytosolic side binding.

Although the results of this report are consistent with the proposed role of VHb being to facilitate oxygen transfer to the terminal respiratory apparatus under hypoxic conditions and increase respiratory efficiency, they do not exclude other possible functions for this protein. For example, there is evidence that it can function as a terminal oxidase under some conditions (42). The related flavohemoglobin from E. coli has been demonstrated to be a nitric-oxide dioxygenase that dioxygenates this free radical to form nitrate (23). This enzyme is inducible under oxygen-limiting conditions and protects the cell from the nitric oxide, which can be generated by the respiratory chain and other oxidation-reduction systems, probably more so under the more reducing conditions of hypoxia. Whether VHb (in conjunction with its flavoprotein metVHb reductase) has a similar role remains to be tested.

    ACKNOWLEDGEMENTS

We are indebted to Dr. Tom Irving for his assistance in computer file interconversions.

    FOOTNOTES

* This work was supported by NSF, National Institutes of Health Department of Science and Technology United States-India Cooperative Grant INT-9811595, NSF, National Institutes of Health Grant MCB-9910356, and a grant from the Department of Biotechnology, Government of India.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence may be addressed. Fax: 312-567-3494; E-mail: dale.webster@iit.edu; kanak@imtech.res.in.

§ Both authors contributed equally to this work. Submitted in partial fulfillment of the requirements for the Ph.D. degree at the Institute of Microbial Technology (for R.) and at the Illinois Institute of Technology (for K. W. H.).

Published, JBC Papers in Press, April 30, 2001, DOI 10.1074/jbc.M009808200

2 D. A. Webster, unpublished observations.

3 K. L. Dikshit, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: VHb, Vitreoscilla hemoglobin; Mb, myoglobin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Wakabayashi, S., Matsubara, H., and Webster, D. A. (1986) Nature 322, 481-483[Medline] [Order article via Infotrieve]
2. Andrew, S. C., Shipley, D., Keen, J. N., Findlay, J. B. C., Harrisson, P. M., and Guest, J. R. (1992) FEBS Lett. 302, 247-252[CrossRef][Medline] [Order article via Infotrieve]
3. Cram, R., Siddiqui, R. A., and Friedrich, B. (1994) J. Biol. Chem. 269, 7349-7354[Abstract/Free Full Text]
4. Zhu, H., and Riggs, A. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5015-5019[Abstract]
5. Couture, M., Yeh, S. R., Wittenberg, B. A., Wittenberg, J. B., Quellet, Y., Rousseau, D. L., and Guertin, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11223-11228[Abstract/Free Full Text]
6. Iijima, M., Shimizu, H., Tanaka, Y., and Urushihara, H. (2000) Cell Struct. Funct. 25, 47-55[CrossRef][Medline] [Order article via Infotrieve]
7. Boerman, S. J., and Webster, D. A. (1982) J. Gen. Appl. Microbiol. 28, 35-43
8. Dikshit, K. L., Spaulding, D., Braun, A., and Webster, D. A. (1989) J. Gen. Microbiol. 135, 2601-2609[Medline] [Order article via Infotrieve]
9. Dikshit, K. L., Dikshit, R. P., and Webster, D. A. (1990) Nucleic Acids Res. 18, 4149-4155[Abstract]
10. Joshi, M., and Diskhit, K. L. (1994) Biochem. Biophys. Res. Commun. 202, 535-542[CrossRef][Medline] [Order article via Infotrieve]
11. Khosla, C., and Bailey, J. E. (1989) J. Bacteriol. 171, 5995-6004[Medline] [Order article via Infotrieve]
12. Khosla, C., and Bailey, J. E. (1988) Nature 331, 633-635[CrossRef][Medline] [Order article via Infotrieve]
13. Khosla, C., Curtis, J. E., DeModena, J., Rinas, U., and Bailey, J. E. (1990) Bio/Technology 8, 849-853[Medline] [Order article via Infotrieve]
14. Liu, S. C., Webster, D. A., and Stark, B. C. (1995) Appl. Microbiol. Biotechnol. 44, 419-424[CrossRef]
15. Khosravi, M., Webster, D. A., and Stark, B. C. (1990) Plasmid 24, 190-194[Medline] [Order article via Infotrieve]
16. DeModena, J. A., Gutierrez, S., Velasco, J., Fernandez, F. J., Fachini, R. A., Galazzo, J. L., Hughes, D. E., and Martin, J. F. (1993) Bio/Technology 11, 926-929[Medline] [Order article via Infotrieve]
17. Liu, S. C., Webster, D. A., Wei, M. L., and Stark, B. C. (1996) Biotechnol. Bioeng. 49, 101-105[CrossRef]
18. Patel, S., Stark, B. C., Hwang, K. W., Dikshit, K. L., and Webster, D. A. (2000) Biotechnol. Prog. 16, 26-30[CrossRef][Medline] [Order article via Infotrieve]
19. Wittenberg, J. A., Bergensen, F. J., Appleby, C. A., and Turner, G. L. (1974) J. Biol. Chem. 249, 4057-4066[Abstract/Free Full Text]
20. Kallio, P. T., Kim, D. J., Tsai, P. S., and Bailey, J. E. (1994) Eur. J. Biochem. 219, 201-208[Abstract]
21. Orii, Y., and Webster, D. A. (1986) J. Biol. Chem. 261, 3544-3547[Abstract/Free Full Text]
22. Webster, D. A. (1987) Adv. Inorg. Biochem. 7, 245-265
23. Gardner, P. R., Gardner, A. M., Martin, L. A., and Satzman, A. L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10378-10383[Abstract/Free Full Text]
24. Khosla, C., and Bailey, J. E. (1989) J. Mol. Biol. 210, 79-89[Medline] [Order article via Infotrieve]
25. Hockney, R. C. (1994) Trends Biotechnol. 12, 456-463[Medline] [Order article via Infotrieve]
26. Tsukihara, T., Aoyama, H., Yamashita, E., Tomizaki, T., Yamaguchi, H., Shinzawa-Itoh, K., Nakashima, R., Yaono, R., and Yoshikawa, S. (1995) Science 269, 1069-1074[Medline] [Order article via Infotrieve]
27. Dikshit, K. L., and Webster, D. A. (1988) Gene (Amst.) 70, 377-386[CrossRef][Medline] [Order article via Infotrieve]
28. Narro, M. L., Adams, C. W., and Cohen, S. N. (1990) J. Bacteriol. 172, 4549-4554[Medline] [Order article via Infotrieve]
29. Joshi, M., Mande, S., and Dikshit, K. L. (1998) Appl. Environ. Microbiol. 64, 2220-2228[Abstract/Free Full Text]
30. Deng, T., Joseph, P. N., and Tsai, M. D. (1994) Gene (Amst.) 93, 224-234
31. Ramandeep, Dikshit, K. L., and Raje, M. (2001) J. Histochem. Cytochem. 49, 355-368[Abstract/Free Full Text]
32. Georgiou, C. D., and Webster, D. A. (1987) Arch. Microbiol. 148, 328-333[Medline] [Order article via Infotrieve]
33. Park, C., Moon, J. Y., Cokic, P., and Webster, D. A. (1996) Biochemistry 35, 11895-11900[CrossRef][Medline] [Order article via Infotrieve]
34. Tyree, B., and Webster, D. A. (1978) J. Biol. Chem. 253, 7635-7637[Abstract]
35. Georgiou, C. D., and Webster, D. A. (1987) Biochemistry 26, 6521-6526[Medline] [Order article via Infotrieve]
36. Hirose, M., and Kano, Y. (1971) Biochim. Biophys. Acta 251, 376-379[Medline] [Order article via Infotrieve]
37. Clark, J. M., Jr., and Switzer, R. L. (1977) Experimental Biochemistry , 2nd Ed. , pp. 159-168, W. H. Freeman and Co., San Francisco, CA
38. Riistama, S., Puustinen, A., Garcia-Horsman, A., Iwata, S., Michel, H., and Wikstrom, M. (1996) Biochim. Biophys. Acta 1275, 1-4[Medline] [Order article via Infotrieve]
39. Tarricone, C., Galizzi, A., Coda, P., Ascenzi, P., and Bolognesi, M. (1997) Structure 5, 497-507[Medline] [Order article via Infotrieve]
40. Vasudevan, S. G., Tang, P., Dixon, N. E., and Poole, R. K. (1995) FEMS Microbiol. Lett. 125, 219-224[CrossRef][Medline] [Order article via Infotrieve]
41. Fung, L. W.-M. (1981) Biochemistry 20, 7162-7166[Medline] [Order article via Infotrieve]
42. Dikshit, R. P., Dikshit, K. L., Liu, Y., and Webster, D. A. (1992) Arch. Biochem. Biophys. 293, 241-245[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.